Minimum inhibitory concentration distributions for first- and second-line antimicrobials against Mycobacterium tuberculosis

References

1. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012; 90:693–698 [View Article][PubMed]
   [Google Scholar]
2. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54:1484–1491 [View Article][PubMed]
   [Google Scholar]
3. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29:565–578[PubMed]
   [Google Scholar]
4. Hoffner SE, Salfinger M. Ad fontes!. Int J Tuberc Lung Dis 2010; 14:260[PubMed]
   [Google Scholar]
5. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009; 37:296–305 [View Article][PubMed]
   [Google Scholar]
6. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med Overseas Ed 2006; 355:1539–1550 [View Article]
   [Google Scholar]
7. Leonard B, Coronel J, Siedner M, Grandjean L, Caviedes L et al. Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2008; 46:3526–3529 [View Article][PubMed]
   [Google Scholar]
8. Updated interim critical concentrations for first-line and second-line DST 2012; WHO Global TB Programme. www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf accessed Sept 2016
9. NCCLS Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Approved Standard. NCCLS document M24-A [ISBN 1-56238-500-3]. Wayne, PA: 2003
   [Google Scholar]
10. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14:282–288[PubMed]
    [Google Scholar]
11. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002; 40:3976–3979 [View Article][PubMed]
    [Google Scholar]
12. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol 2013; 51:393–401 [View Article][PubMed]
    [Google Scholar]
13. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64:786–793 [View Article][PubMed]
    [Google Scholar]
14. Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G et al. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10. Clin Microbiol Infect 2015; 21:148.e5–14148 [View Article][PubMed]
    [Google Scholar]
15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0; 2016 www.eucast.org
16. Sheen P, Couvin D, Grandjean L, Zimic M, Dominguez M et al. Genetic diversity of Mycobacterium tuberculosis in Peru and exploration of phylogenetic associations with drug resistance. PLoS One 2013; 8:e6587312 [View Article][PubMed]
    [Google Scholar]
17. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M et al. Multidrug-resistant tuberculosis around the world: what progress has been made?. Eur Respir J 2015; 45:150–160 [View Article][PubMed]
    [Google Scholar]